MBRX Borrow Market Heats Up Ahead of Next Week's Earnings

Moleculin Biotech enters its May 19 earnings report with the borrow market under real pressure — and a short score near the top of the universe.

The most striking development this week is how rapidly shorts have built. Short interest rose 296% over the past month, reaching 8.1% of free float. That is a meaningful position for a micro-cap biotech. The week ended with 430,000 shares short — down roughly 14% on the final day from a peak of 503,000 on Monday, suggesting some covering after a heavy build. Borrowing costs have followed the demand: cost to borrow climbed to 70.1% annualised, up 17% on the week and near recent highs. The borrow market has clearly tightened in tandem.

Availability reinforces how squeezed the lending pool has become. At 35.2% of short interest, availability is tight — meaning less than one share is available to borrow for every three already lent out. That compares with near-full availability in early April, when utilisation was running below 20%. The shift has been rapid and consistent. Borrow availability dropped from loose to tight in a matter of weeks, coinciding almost exactly with the acceleration in short positions from late April onward. The ORTEX short score of 77.4 — ranking in roughly the 96th percentile — reflects the full picture: high and rising short interest, costly borrow, and constrained availability all converging.

The stock's RSI-14 of 33.6 tells a different story from the direction of those short builds. The price has fallen 6% on the week and 11% over the past month to $2.34, putting technicals in oversold territory. That setup — heavy short positioning meeting a deeply oversold tape — is the central tension heading into the May 19 print. Correlated peer ALP surged 15% on the day and 13% on the week, while PRTA fell 16% on the week, illustrating how wide the dispersion is among small biotech names right now.

Looking at prior earnings reactions, the pattern is mixed. The last four events produced moves of +9.2%, -4.6%, +0.4%, and -11.0% on the first day. The five-day follow-through has been even wider, ranging from -33% to +15%. There is no consistent directional pattern — what stands out is the magnitude. The combination of a heavily shorted float, a tight borrow market, and a historically volatile earnings reaction profile means the May 19 release carries an unusually charged setup on both sides.

There is no fresh analyst coverage in the data to lean on, and conventional valuation metrics are not meaningful for a pre-revenue biotech at this stage. What will matter most next week is the clinical or financial narrative in the earnings release itself — and whether the current short positioning, built so aggressively over the past month, faces any catalyst for reversal or continuation.